Clinical trial NCT01896973: Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (US)
Official title: Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (US)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Benign Prostatic Hyperplasia (BPH)
Keywords: Benign Prostatic Hyperplasia
BPH
LUTS
Vortx Rx
Histotripsy
Lead sponsor: HistoSonics, Inc.
Sponsor class: INDUSTRY
First posted: 2013-07-11
Enrollment: 28
Sex: MALE
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The HistoSonics' Histotripsy BPH Device, the Vortx Rx, is a portable ultrasound therapy device. The purpose of this study is to assess and monitor the performance of the Vortx Rx for initial safety and efficacy for the treatment of Benign Prostatic Hyperplasia.

Detailed description: Prospective, single-arm study

Eligibility criteria: Inclusion Criteria:

1. Diagnosis of BPH and eligible for endoscopic BPH surgery including TURP, PVP, electrovaporization.
2. Prostate volumes 30 - 80 gm based on transrectal ultrasound
3. Men ≥ 50 years of age
4. IPSS symptom score ≥ 13 and IPSS bother score \> 2 (see Appendix B for IPSS questionnaire)
5. Baseline peak flow rate Qmax ≤ 15 cc/s with voided volume at least 125 cc

Exclusion Criteria:

1. History of prostate or bladder cancer, pelvic radiation, untreated bladder stones, urethral strictures/bladder neck contracture (BNC), renal insufficiency (i.e. creatinine \> 1.4)
2. Neurogenic bladder, Parkinson's disease
3. Prior treatment for urinary incontinence
4. Micturition frequency AND urgency. Micturition frequency defined as \> 8 micturitions per 24 hours as assessed by a thorough subject history including the question: "On average, how many times do you void during a 24 hour period? // \< 4, 5-7, 8 or more." Urgency defined as an uncontrollable urge to void that occurs \> 3 per 24 hours as assessed through the subject history/question: "On average, how many times a day do you have an uncontrollable urgency to void? // 0, 1-2, 3 or more?"
5. Intravesical prostate lobe protrusion \> 1 cm on TRUS. Note: this is distinct from lateral lobes protruding up to the bladder such as an intravesical protrusion without median lobe
6. Active UTI (i.e. must have a screening urinalysis without signs of infection or a negative urine culture)
7. PVR \> 250 at time of enrollment or catheter dependent bladder drainage
8. History of chronic prostatitis within the last 5 years
9. Not able to temporarily discontinue aspirin, Coumadin, Plavix and any other anticoagulant at least seven days prior to the time of treatment
10. History of known bleeding disorders (e.g. von Willebrand disease \[VWD\]) and subjects determined to have a bleeding disorder by prothrombin time (PT) and partial thromboplastin time (PTT) tests.
11. Prior BPH prostate procedures (e.g. TUMT, TUNA, water induced thermotherapy \[WIT\], TURP, PVP)
12. Men with confirmed or suspected malignancy of the prostate based on a digital rectal exam (DRE), prostate biopsy or PSA \> 10 ng/mL. Men with free PSA \< 25% and PSA between 2.5 and 10 ng/mL may only be enrolled after a negative biopsy. If a prior prostate biopsy was performed within one year of enrollment and was negative for cancer, repeat biopsy is not required if in the investigator's judgment there is no clinical evidence to support biopsy reassessment. If a biopsy is required, the subject shall have a six-week waiting period between the biopsy and histotripsy treatment, if he is otherwise deemed eligible to participate in the study.
13. Men interested in future fertility
14. Declines or unable to provide informed consent
15. Non-English-speaker
16. Life expectancy estimated to be less than one year
17. Unable or unwilling to complete all required questionnaires and follow-up assessments
18. In the opinion of the investigator, it is not in the subject's best interest to participate in the study.

Primary outcomes:
measure: Safety of the Vortx Rx for treatment of symptomatic BPH
timeFrame: 1 Day, 1, 3 and 6 months
Secondary outcomes:
measure: Initial prostate histotripsy treatment efficacy
timeFrame: 1, 3 and 6 months
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: Univerisity of Michigan
state: Michigan
city: Toledo
country: United States
facility: ProMedica Parkway Surgery Center
state: Ohio
Study officials:
affiliation: ProMedica Parkway Surgery Center
name: Timonthy Schuster, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Michigan
name: John Wei, MD
role: PRINCIPAL_INVESTIGATOR
References: